Factors Associated with Inferior Outcomes in Patients with Advanced Urothelial Carcinoma
2 Mins
Enfortumab vedotin plus pembrolizumab (EV+P) is the preferred first-line (1L) regimen for patients with advanced urothelial carcinoma…